

1FWB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GRETZKE, et. al.

Examiner: LEE, Susannah E.

Art Unit: 1626

Application No.: 10/789,865

Filed: February 27, 2004

Title: **Cycloalkyl derivatives having
bioisosteric carboxylic acid
groups, processes for their
preparation and their use as
pharmaceuticals**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450, on

Date of Deposit September 29, 2005

Brian Pritchett

Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.


- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

10/05/2005 HLE333 00000012 181982 10789865

01 FC:1806 180.00 DA

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,


Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626
Aventis Docket No. DEAV2003/0018 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GRETZKE, et. al.

Examiner: LEE, Susannah E.

Art Unit: 1626

Application No.: 10/789,865

Filed: February 27, 2004

Title: **Cycloalkyl derivatives having
bioisosteric carboxylic acid
groups, processes for their
preparation and their use as
pharmaceuticals**

Certificate of Mailing or Transmission

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit September 29, 2005

Printed Name of Person Signing Certificate **Brian Pritchett**

Signature *Brian Pritchett*

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,

Barbara E. Kurys

Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0018 US NP

☒

+


Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 7

Application Number	10/789,865
Filing Date	02-27-2004
First Named Inventor	GRETZKE, et. al.
Group Art Unit	1626
Examiner Name	LEE, Susannah E.
Attorney Docket Number	DEAV2003/0018 - US - NP



[illegible]

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		EP	0 462 884 A1		VINCENT, et. al.	12-27-2001		
		WO	00/40569		HODSON, et. al.	07-13-2000		
		WO	00/63208		DORWALD, et. al.	10-26-2000		
		WO	00/64876		JAYYOSI, et. al.	11-02-2000		
		WO	00/64888		JAYYOSI, et. al.	11-02-2000		
		WO	00/66585		HORVATH, et. al.	11-09-2000		
		WO	00/71549		BROUGH, et. al.	11-30-2000		
		WO	00/78312 A1		SAHOO, et. al.	12-28-2000		
		WO	01/04146 A2		OLSEN, et. al.	01-18-2001		
		WO	01/09111 A1		BRINER, et. al.	02-08-2001		

Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

☒

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/789,865
				Filing Date	02-27-2004
				First Named Inventor	GRETZKE, et. al.
				Group Art Unit	1626
				Examiner Name	LEE, Susannah E.
				Attorney Docket Number	DEAV2003/0018 - US - NP
Sheet	2	of	7		

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials ²	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	01/21602 A1		CHENG, et. al.	03-29-2001		
		WO	01/40169 A1		HALLGREN, et. al.	06-07-2001		
		WO	01/40171 A1		BOJE, et. al.	06-07-2001		
		WO	01/72290 A2		DEMUTH, et. al.	10-04-2001		
		WO	01/81327 A1		OONODA, et. al.	11-01-2001		
		WO	01/83451		IKUTA, et. al.	11-08-2001		
		WO	01/85695 A1		LI, et. al.	11-05-2001		
		WO	01/91752 A1		BAKSHI, et. al.	12-06-2001		
		WO	01/94300		DEFOSSA, et. al.	12-13-2001		
		WO	02/051820		TAJIMA, et. al.	07-04-2002		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

☒

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/789,865	
			Filing Date	02-27-2004	
			First Named Inventor	GRETZKE, et. al.	
			Group Art Unit	1626	
			Examiner Name	LEE, Susannah E.	
Sheet	3	of	7	Attorney Docket Number	DEAV2003/0018 - US - NP

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	02/064549 A1		HAYWARD, et. al.	08-22-2002		
		WO	02/096864		DEFOSSA, et. al.	12-05-2002		
		WO	02/38541 A1		FUKUSHIMA, et. al.	05-16-2002		
		WO	02/46146 A1		TAKAHASHI, et. al.	06-13-2002		
		WO	02/50027		GLOMBIK, et. al.	06-27-2002		
		WO	03/004458 A1		GUSTAVSSON, et. al.	01-16-2003		
		WO	03/020269		GLOMBIK, et. al.	03-13-2003		
		WO	03/040174 A2		DEMUTH, et. al.	05-15-2003		
		WO	03/066581 A1		HENRY, et. al.	08-14-2003		
		WO	03/084922		DEFOSSA, et. al.	10-16-2003		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

☒

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/789,865
				Filing Date	02-27-2004
				First Named Inventor	GRETZKE, et. al.
				Group Art Unit	1626
				Examiner Name	LEE, Susannah E.
Sheet	4	of	7	Attorney Docket Number	DEAV2003/0018 - US - NP

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	03/084923		DEFOSSA, et. al.	10-16-2003		
		WO	03/104188		SCHOENAFINGER, et. al.	12-18-2003		
		WO	94/18183		BRIEADDY, et. al.	08-18-1994		
		WO	94/18184		BRIEADDY, et. al.	08-18-1994		
		WO	96/38428		MAEDA, et. al.	12-05-1996		
		WO	97/26265		NIELSEN, et. al.	07-24-1997		
		WO	97/41097		LOHRAY, et. al.	11-06-1997		
		WO	98/08871		KNUDSEN, et. al.	03-05-1998		
		WO	98/19998		VILLHAUER, et. al.	05-14-1998		
		WO	99/03861		NIELSEN, et. al.	01-28-1999		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/789,865
				Filing Date	02-27-2004
				First Named Inventor	GRETZKE, et. al.
				Group Art Unit	1626
				Examiner Name	LEE, Susannah E.
				Attorney Docket Number	DEAV2003/0018 - US - NP
Sheet	5	of	7		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/789,865	
			Filing Date	02-27-2004	
			First Named Inventor	GRETZKE, et. al.	
			Group Art Unit	1626	
			Examiner Name	LEE, Susannah E.	
			Attorney Docket Number	DEAV2003/0018 - US - NP	
Sheet	6	of	7		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		ASAKAWA, A., et. al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Reserch; Vol. 33(9); 2001; pp 554-558		
		BERGER, J., et. al., The Mechanisms of Action of PPARs, Annul. Rev. Med.; Vol. 53; 2002; pp 409-435		
		FRUCHART, J.C., et. al., PPARs, Metabolic Disease and Atherosclerosis, Pharmacological Research; Vol. 44, No. 5; 2001' pp 345-352		
		KERSTEN, S., et. al., Roles of PPARs in Health and Disease, Nature; Vol. 405; May 25, 2000; pp 421-424		
		KLIEWER, S.A., et. al., Peroxisome Proliferator-Activated Receptors: From Genes to Physiology, Recent Prog. Horm Res.; Vol. 56; 2001; pp 239-263		
		LEE, D.W., et. al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future; Vol. 26(9); 2001; pp 873-881		
		MOTOJIMA, K., et. al. Peroxisome Proliferator-Activated Receptor (PPAR): Structure, Mechanisms of Activation and Diverse Functions, Cell Structure and Function; Vol. 18; 1993; pp 267-277		
		OKADA, H., et. al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull.; Vol. 42(1); 1994; pp 57-61		
		PINEDA TORRA, I., et. al., Peroxisome Proliferator-activated Receptors: from Transcriptional Control to Clinical Practice, Curr. Opin. Lipidol; Vol. 12; 2001; pp 245-254		
		PINEDA TORRA, I., et. al., Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging, Curr. Opin. Lipidol; Vol. 10; 1999; pp 151-159		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/789,865	
			Filing Date	02-27-2004	
			First Named Inventor	GRETZKE, et. al.	
			Group Art Unit	1626	
			Examiner Name	LEE, Susannah E.	
Sheet	7	of	7	Attorney Docket Number	DEAV2003/0018 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VIDAL-PUIG, A., et. al., Regulation of PPAR γ Gene Expression by Nutrition and Obesity in Rodents, J. Clin. Invest.; Vol. 97, No. 11, 1996; pp 2553-2561	
		WILLSON, T., M., et. al., The PPARs: From Orphan Receptors to Drug Discovery, Journal of Medicinal Chemistry; Vol. 43, NO. 4; 2000; pp 527-550	
		ZUNFT, H.J.F., et. al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances in Natural Therapy; Vol. 18, No. 5; Sept.-Oct, 2001; pp 230-236	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.